Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Lampert Mark N
Relationship:   10% Owner
City:   San Francisco
State:   CA
   
Insider Summary:
  
   
Companies Owned :   44    
Direct Shares   110,838,010    

Indirect Shares

   88,557,834      
Direct Value   $1,474,869,951    

Indirect Value

   $1,628,714,992      
Total Shares   199,395,844      
Total Value   $3,103,584,943      


Repligen Corp $554,842,288 Dynavax Technologies Corp $68,123,561 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,347,515 Alpine Immune Sciences Inc $13,107,624 Glycomimetics Inc $174,005 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,841,923 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $27,498,164 Merus Nv $10,420,083 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $515,876 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $258,343,091 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $3,115,299 Structure Therapeutics Inc. $184,709,694 Engene Holdings Inc. $31,633,377 Allakos Inc. $19,412,318 Repligen Corp $554,842,288 Dynavax Technologies Corp $68,123,561 Adolor Corp $0 Arqule Inc $15,426,100 Astex Pharmaceuticals Inc $0 Infinity Pharmaceuticals Inc $1 XOMA Corporation $43,347,515 Alpine Immune Sciences Inc $13,107,624 Glycomimetics Inc $174,005 Xenon Pharmaceuticals Inc. $0 Concert Pharmaceuticals, Inc. $1,419,460 Syndax Pharmaceuticals Inc $1,841,923 Immune Design Corp. $0 Pieris Pharmaceuticals, Inc. $2,970,733 Calithera Biosciences, Inc. $9,609 Five Prime Therapeutics Inc $237,959,230 Cytokinetics Inc $27,498,164 Merus Nv $10,420,083 Ideaya Biosciences, Inc. $0 Kymera Therapeutics, Inc. $0 Eledon Pharmaceuticals Ord Shs $515,876 Olema Pharmaceuticals, Inc. $0 Cytomx Therapeutics, Inc. $0 Repare Therapeutics Inc. $0 Verastem, Inc. $258,343,091 ESSA Pharma Inc $0 Third Harmonic Bio, Inc. $3,115,299 Structure Therapeutics Inc. $184,709,694 Engene Holdings Inc. $31,633,377 Allakos Inc. $19,412,318
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    50   
    13    

     Stock price went up :
    40   
    4    
     Stock price went down :
    10   
    9    
   
     Gain/Loss Ratio :
   4.0   
   4.0   
     Percentage Gain/Loss :
   103.0%
 -82.1%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Arena Pharmaceuticals Inc ARNA Director, 10% Owner 2003-10-17 0 2003-10-17 4,520,212    Premium*  
            Repligen Corp RGEN 10% Owner 2009-05-15 3,216,850 0    Premium*  
            Dynavax Technologies Corp DVAX Indirect Beneficial Ow... 2009-06-19 6,193,051 2009-06-19 18,579,153    Premium*  
            Adolor Corp ADLR 10% Owner 2009-09-22 4,123,551 2009-09-22 12,370,653    Premium*  
            Gyre Therapeutics GYRE 10% Owner 0 2012-11-08 1,052,258    Premium*  
            Arqule Inc ARQL 10% Owner 2018-05-30 771,305 2010-04-05 12,624,219    Premium*  
            Astex Pharmaceuticals Inc ASTX 10% Owner 2010-04-20 5,583,399 2010-04-20 16,750,197    Premium*  
            Capstone Therapeutics Corp CAPS See Explanation of Res... 2011-06-27 0 2017-07-14 890,487    Premium*  
            Ligand Pharmaceuticals Inc LGND See Explanation of Res... 0 2014-03-25 130,175    Premium*  
            Icagen Inc ICGN 10% Owner 2011-09-07 0 2011-09-07 625,400    Premium*  
            Palatin Technologies Inc PTN 10% Owner 0 2014-02-27 2,494,521    Premium*  
            Neurocrine Biosciences Inc NBIX 10% Owner 2011-10-10 0 2011-10-12 3,527,700    Premium*  
            Kent International Inc KNTH See Explanation of Res... 2011-12-23 0 2011-12-23 0    Premium*  
            Chemocentryx, Inc. CCXI 10% Owner 0 2012-11-06 3,750,277    Premium*  
            Rigel Pharmaceuticals Inc RIGL 10% Owner 0 2013-06-07 7,761,738    Premium*  
            Cascadian Therapeutics, Inc CASC 10% Owner 2013-06-05 0 2015-02-05 1,898,293    Premium*  
            Tobira Therapeutics Inc TBRA See Explanation of Res... 0 2014-03-21 1,121,221    Premium*  
            Cti Biopharma Corporation CTIC See Explanation of Res... 2023-06-26 0 2023-06-26 0    Premium*  
            Infinity Pharmaceuticals Inc INFI 10% Owner 2021-02-11 534,847 2016-12-01 0    Premium*  
            XOMA Corporation XOMA Director, 10% Owner 2023-01-06 1,693,924 2023-01-06 361,774    Premium*  
            Alpine Immune Sciences Inc ALPN 10% Owner 2017-06-20 201,811 2017-05-09 0    Premium*  
            Glycomimetics Inc GLYC 10% Owner 2020-11-04 630,453 0    Premium*  
            Xenon Pharmaceuticals Inc. XENE 10% Owner 2018-03-27 59,464 2017-06-06 0    Premium*  
            Concert Pharmaceuticals, Inc. CNCE 10% Owner 2019-06-10 169,589 2017-10-19 0    Premium*  
            Syndax Pharmaceuticals Inc SNDX 10% Owner 2018-06-18 85,038 2018-06-18 0    Premium*  
            Immune Design Corp. IMDZ 10% Owner 2018-12-04 370,391 2018-12-04 0    Premium*  
            Pieris Pharmaceuticals, Inc. PIRS 10% Owner 2023-05-11 20,333,557 2019-01-30 0    Premium*  
            Calithera Biosciences, Inc. CALA 10% Owner 2020-05-21 480,432 0    Premium*  
            Five Prime Therapeutics Inc FPRX 10% Owner 2021-03-04 6,262,085 0    Premium*  
            Cytokinetics Inc CYTK See Explanation of Res... 2020-12-09 463,244 2019-12-10 0    Premium*  
            Merus Nv MRUS 10% Owner 2021-10-08 232,747 0    Premium*  
            Ideaya Biosciences, Inc. IDYA See Explanation of Res... 2021-02-02 233,150 2020-06-19 0    Premium*  
            Kymera Therapeutics, Inc. KYMR See Remarks and Footno... 2023-11-03 294,632 2020-08-21 0    Premium*  
            Eledon Pharmaceuticals Ord Shs ELDN 10% Owner 2024-05-09 220,460 0    Premium*  
            Olema Pharmaceuticals, Inc. OLMA Director, 10% Owner 2023-09-12 524,151 2023-09-14 99,556    Premium*  
            Cytomx Therapeutics, Inc. CTMX 10% Owner 2020-12-18 5,468,599 0    Premium*  
            Rain Therapeutics Inc. RAIN See Remarks; Former 10... 2024-01-25 0 2021-04-23 0    Premium*  
            Repare Therapeutics Inc. RPTX 10% Owner 2023-11-16 548,938 0    Premium*  
            Verastem, Inc. VSTM 10% Owner 2022-01-25 19,630,934 0    Premium*  
            ESSA Pharma Inc EPIX 10% Owner 2022-07-11 8,561,841 0    Premium*  
            Third Harmonic Bio, Inc. THRD 10% Owner 2022-12-20 241,309 2022-12-20 0    Premium*  
            Structure Therapeutics Inc. GPCR 10% Owner 2023-05-10 5,173,941 0    Premium*  
            Engene Holdings Inc. ENGN 10% Owner 2023-10-31 2,221,445 0    Premium*  
            Allakos Inc. ALLK 10% Owner 2024-01-16 16,312,872 0    Premium*  
* Premium Members only  

Records found :    356         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 5 of 15
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
XOMA XOMA Corporation 10% Owner   –       –       •   2020-09-22 4 B $18.45 $220,445 D/D 11,951 1,743,503 2.45 %
XENE Xenon Pharmaceuticals Inc... 10% Owner   –       –       •   2017-06-21 4 B $4.00 $48,592 D/D 12,148 288,114 2.37 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2012-10-26 4 B $15.26 $190,926 I/I 12,515 737,551 1.5 -
CAPS Capstone Therapeutics Cor... See Explanation of Responses   –       –       •   2011-06-29 4 B $0.25 $3,215 I/I 12,950 3,180,750 1.42 -
XOMA XOMA Corporation 10% Owner   –       –       •   2019-05-14 4 B $14.74 $203,664 D/D 13,816 746,454 2.45 -
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-10-04 4 B $12.78 $183,961 I/I 14,400 362,080 1.5 -
CASC Cascadian Therapeutics, I... See Explanation of Responses   –       –       •   2013-06-05 4 B $1.75 $26,775 I/I 15,300 2,308,607 1.5 -
FPRX Five Prime Therapeutics I... 10% Owner   –       –       •   2019-10-04 4 B $3.74 $59,800 D/D 16,000 299,487 2.45 -
XOMA XOMA Corporation 10% Owner   –       –       •   2020-08-31 4 B $18.48 $295,782 D/D 16,005 1,716,941 2.45 %
LGND Ligand Pharmaceuticals In... See Explanation of Responses   –       –       •   2011-08-18 4 B $11.91 $197,371 I/I 16,571 1,652,562 1.5 -
XOMA XOMA Corporation Director   –       •       •   2022-09-23 4 B $16.50 $273,850 D/D 16,600 1,597,695 3.92 %
XOMA XOMA Corporation 10% Owner   –       –       •   2020-09-23 4 B $18.20 $311,016 D/D 17,089 1,750,704 2.45 %
RAIN Rain Therapeutics Inc. See Explanation of Responses   –       –      –    2021-05-19 4 B $15.88 $274,290 D/D 17,268 104,761 2.44 -
XOMA XOMA Corporation 10% Owner   –       –       •   2020-09-01 4 B $18.87 $331,515 D/D 17,572 1,724,613 2.45 %
ALPN Alpine Immune Sciences In... 10% Owner   –       –       •   2017-06-20 4 B $2.25 $40,064 D/D 17,806 201,811 2.37 -
XOMA XOMA Corporation 10% Owner   –       –       •   2018-12-10 4 B $14.54 $262,972 D/D 18,081 657,078 2.45 -
CAPS Capstone Therapeutics Cor... See Explanation of Responses   –       –       •   2011-07-26 4 B $0.25 $4,600 I/I 18,400 3,730,300 1.42 -
XENE Xenon Pharmaceuticals Inc... 10% Owner   –       –       •   2017-08-15 4 B $2.41 $45,489 D/D 18,858 1,077,694 2.37 -
KYMR Kymera Therapeutics, Inc. See Remarks and Footnotes   –       •      –    2023-01-12 4 B $31.24 $590,391 D/D 18,897 1,888,351 2.39 -
ALPN Alpine Immune Sciences In... 10% Owner   –       –       •   2017-05-30 4 B $2.30 $43,389 D/D 18,900 189,776 2.37 -
XOMA XOMA Corporation Director   –       •       •   2023-01-05 4 B $18.39 $349,319 D/D 19,000 1,617,064 3.92 %
CAPS Capstone Therapeutics Cor... See Explanation of Responses   –       –       •   2011-07-14 4 B $0.25 $4,925 I/I 19,700 3,212,300 1.42 -
IDYA Ideaya Biosciences, Inc. 10% Owner   –       –       •   2020-06-22 4 B $13.93 $274,960 D/D 19,732 237,394 2.45 -
FPRX Five Prime Therapeutics I... 10% Owner   –       –       •   2019-10-30 4 B $3.89 $78,157 D/D 20,081 348,323 2.45 -
XOMA XOMA Corporation 10% Owner   –       –       •   2018-11-15 4 B $13.31 $281,361 D/D 21,141 473,453 2.45 -
  356  Records found
  1   2   3   4   5  6   7   8   9   10   11   12   13   14   15      
  Page 5 of 15  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us